Xiumin Wu
San Bruno,CA
Summary
Enthusiastic, dedicated, self-driving, strong problem solving and creative researcher with the ability to work independently and collaboration with others in multidisciplinary drug discovery project teams. Strong experienced in designing and implementing in vivo pharmacology studies such efficacy, tolerability, and pharmacodynamic (PD) studies from early stage research and target validation to late stage clinical candidates for drug discovery. Ability to think critically, independently to drive project forward and demonstrated troubleshooting and problem-solving skills More than 10 years’ experience in pharmaceutical and biotech industry in designing and performing in vivo PK/ADME, PD and toxicological studies for screening drug candidates (small and large molecules) in rats, guinae Pi g mice and other species. Extensive designing and hands-on (IP, IV, SC, and PO dosing, blood and tissue collection) and expertise of employing multiple in vivo models including like Xenograft, Allograft, Metastasis, Patient derived xenograft cancer models, as well as Type 2 diabetes, Stroke, colitis (DSS, CD45RBhi T cell transfer, IL-10 KO), Arthritis (CIA, CAIA) lupus(NZB/W, MRL-lpr, Imiquimod), Asthma (ova and HDM), wound healing and renal ischemic-reperfusion injury to evaluate drug mechanism and function of efficacy. Protein purification and characterization, (chromatography such as, affinity, ion-exchange, hydrophobic, and size exclusion), ELISAs, Cell-based assay development, primary cells and tissue culture techniques, FACS, receptor binding assays and/or cell-based HTS assays development, DNA/RNA isolation, immunohistochemistry and H&E staining, and drug formulation and quality control of drug substance for release and stability tests. Effective team players in cross-functional teams, interpret experiments results independently with research resulting in 72 publications including top-tier journals Nature and Cell.
Overview
44
44
years of professional experience
8
8
Certifications
Work History
Life science Sr, Scientist
Calico
02.2024 - Current
- I am lab-focused, scientifically curious, use multi-disciplinary approaches to develop in vivo models responsible for designing and executing experiments exploring and understanding the pharmacology of drug targets; generating, and communicating pharmacology and preclinical data to support the progression of research projects, and providing technical expertise that enable to therapeutic area scientists to study the molecular mechanisms of signaling in aging and oncology
- I am using multiple tumor models to demonstrate and study cancer metabolism and T cell signaling in the PTPN2/PTPN1 inhibitor, anti-PAPPA, cancer vaccines, and anti-tumor immunity program
- To use multi-disciplinary approaches to develop in vivo models to Elucidate mechanisms of action and resistance to enable in-depth understanding of fundamental disease biology, as well as experimentally validate Client therapeutic targets
- To lead the development of translational pharmacology strategies, PK/PD, and disease models
- Significantly contributed ideas and experiments to 5 scientific publications
- Dsign and conducted lab-based research projects involving a wide repertoire of experimental techniques such as conventional/spectral flow cytometry, biochemistry, cell/molecular biology, and immune function assays.
- Self-motivated, with a strong sense of personal responsibility.
- Excellent communication skills, both verbal and written.
- Skilled at working independently and collaboratively in a team environment.
- Proven ability to learn quickly and adapt to new situations.
- Worked well in a team setting, providing support and guidance.
- Managed time efficiently in order to complete all tasks within deadlines.
- Assisted with day-to-day operations, working efficiently and productively with all team members.
- Worked effectively in fast-paced environments.
- Passionate about learning and committed to continual improvement.
- Worked flexible hours across night, weekend, and holiday shifts.
- Demonstrated respect, friendliness and willingness to help wherever needed.
- Strengthened communication skills through regular interactions with others.
- Paid attention to detail while completing assignments.
- Organized and detail-oriented with a strong work ethic.
- Adaptable and proficient in learning new concepts quickly and efficiently.
- Learned and adapted quickly to new technology and software applications.
- Resolved problems, improved operations and provided exceptional service.
- Proved successful working within tight deadlines and a fast-paced environment.
- Participated in team projects, demonstrating an ability to work collaboratively and effectively.
- Used strong analytical and problem-solving skills to develop effective solutions for challenging situations.
therapeutics Sr Pharmacology manager
Nkarta
01.2019 - 02.2021
- Experienced handle xenogeneic GvHD, T-cell alloreactivity, immunity of murine models such as NSG mice, humanized mice reconstituted with human immune cells to understand mechanism
- Pay an important role in developing in vivo analytical methods (IVIS imaging, tissue distributions) for developing NK, NK+T cellular therapy products
- Independently design, develop, plans and executes a broad range of subcutaneous, systemic and orthotopic in vivo oncology mouse models for characterization of NK cell products and to explore product efficacy, PKPD and toxicity profile
- Presents study results at team or department meetings to contribute for multiple projects
- Prepares study protocols, reports, technology transfer documentation, and regulatory documents for clinical trials.
- Accomplished multiple tasks within established timeframes.
- Enhanced customer satisfaction by resolving disputes promptly, maintaining open lines of communication, and ensuring high-quality service delivery.
- Resolved staff member conflicts, actively listening to concerns and finding appropriate middle ground.
- Cross-trained existing employees to maximize team agility and performance.
- Developed and maintained relationships with customers and suppliers through account development.
- Managed budgets effectively, ensuring optimal financial performance while investing in necessary resources for business growth.
- Achieved departmental goals by developing and executing strategic plans and performance metrics.
- Built high-performing teams through effective recruitment, onboarding, and talent development initiatives.
- Mentored junior team members for career advancement, fostering a pipeline of future leaders within the organization.
- Developed a strong company culture focused on employee engagement, collaboration, and continuous learning opportunities.
- Boosted employee morale and reduced turnover through development and implementation of comprehensive rewards and recognition program.
- Reduced operational costs through comprehensive process improvement initiatives and resource management.
- Streamlined workflows by identifying bottlenecks in existing systems and implementing appropriate solutions.
- Developed and executed marketing strategies that effectively communicated brand values, increasing brand recognition.
- Facilitated team brainstorming sessions that led to innovative solutions for long-standing operational challenges.
- Increased market share with strategic business development efforts, expanding into untapped markets.
- Achieved significant cost savings by renegotiating contracts with key vendors, without compromising service quality.
- Improved customer satisfaction scores by overhauling customer service protocols and training staff in customer engagement techniques.
- Fostered partnerships with industry leaders, enhancing company's reputation and creating new business opportunities.
- Enhanced product quality by instituting rigorous quality control procedures, resulting in fewer customer complaints.
- Enhanced team productivity by implementing agile methodologies, leading to more efficient project completion.
- Spearheaded transition to remote work during global health crisis, ensuring business continuity and employee safety.
- Negotiated favorable terms with suppliers, cutting operational costs while maintaining quality of service.
- Implemented customer feedback mechanisms to gather insights, using this information to guide strategic planning and decision-making.
- Developed comprehensive risk management plan, minimizing potential disruptions to business operations.
- Led cross-functional teams to achieve project goals, fostering collaboration and innovation.
- Conducted market research to identify customer needs and adjusted product offerings accordingly, increasing customer satisfaction.
- Streamlined project delivery processes, significantly reducing time to market for new product launches.
- Coordinated with IT department to upgrade technology infrastructure, enhancing operational efficiency and data security.
- Managed budget allocations to prioritize spending on high-impact projects, optimizing resource utilization.
- Oversaw inventory management, optimizing stock levels, and reducing waste.
- Organized professional development programs for staff, leading to improved performance and skill sets.
- Maintained positive customer relations by addressing problems head-on and implementing successful corrective actions.
- Established team priorities, maintained schedules and monitored performance.
- Evaluated employee performance and conveyed constructive feedback to improve skills.
- Successfully managed budgets and allocated resources to maximize productivity and profitability.
- Assisted in organizing and overseeing assignments to drive operational excellence.
- Defined clear targets and objectives and communicated to other team members.
- Maintained professional demeanor by staying calm when addressing unhappy or angry customers.
- Recruited, interviewed and hired employees and implemented mentoring program to promote positive feedback and engagement.
- Used industry expertise, customer service skills and analytical nature to resolve customer concerns and promote loyalty.
- Developed detailed plans based on broad guidance and direction.
- Set aggressive targets for employees to drive company success and strengthen motivation.
- Leveraged data and analytics to make informed decisions and drive business improvements.
- Identified and communicated customer needs to supply chain capacity and quality teams.
- Improved staffing during busy periods by creating employee schedules and monitoring call-outs.
- Trained personnel in equipment maintenance and enforced participation in exercises focused on developing key skills.
- Planned, created, tested and deployed system life cycle methodology to produce high quality systems to meet and exceed customer expectations.
- Managed senior-level personnel working in marketing and sales capacities.
- Controlled resources and assets for department activities to comply with industry standards and government regulations.
- Opened and closed location and monitored shift changes to uphold successful operations strategies and maximize business success.
- Streamlined and monitored quality programs to alleviate overdue compliance activities.
- Cultivated positive rapport with fellow employees to boost company morale and promote employee retention.
- Launched quality assurance practices for each phase of development
- Reduced waste and pursued revenue development strategies to keep department aligned with sales and profit targets.
- Established performance goals for employees and provided feedback on methods for reaching those milestones.
Senior Scientific Research
Genentech, Inc
01.2013 - 06.2019
- Work together with immunology discovery project scientists on earlier or late-stage lead optimization of SMI or antibodies to evaluate PK/PD relationships, in vivo efficacy and immune cell function
- Provide input and tactical planning to nonclinical development strategy for drug discovery
- Cellular and in vivo model development in relevant areas of immunology and tumor immune oncology
- E.g
- Using immunology mouse models to study the role of the tumor suppress of BAP1 in melanoma, OVA induced Th2 cytokine production and airway inflammation during T cell activation and in vivo differentiation of TH17 cells link to the Notch pathway
- Design and execute in vivo strategies for testing antibody mechanism of action
- E.g
- Linking animal models to human disease, including rheumatoid arthritis, systemic lupus erythematosus, and asthma, Lead and hand on those models to evaluate iJAK-1, TRAP1, IRAK4 small molecules inhibitor, CRTh2, anti-human tryptase-b1, Tpl-2 , anti-LI-33, anti-Jag1 mechanism of action and efficacy for supporting IND filing
- Design, plan and develop novel Staphylococcus aureus infected wound healing in db/db mice model to evaluate the mechanism action of IL22-Fc, VEFG and PDGF and resulting to make IL22-Fc to late stage clinical candidate
- Design, plan and develop bilateral renal ischemic-reperfusion injury mouse model by using RIP3 kd.KI mice and small molecular to investigate the biology functions of RIP1 kinase dead KI
- Design, plan and develop Influenza Virus induced exacerbation in House Dust Mite mouse model of asthma to evaluate the mechanism action of small molecular inhibiters and resulting to late stage clinical candidate
- Design, plan and develop bleomycin induced pulmonary fibrosis model
- Design, plan and implement in vivo studies to assess immune-mediated mechanisms of anti-tumor activity, T-cell trafficking to the tumor microenvironment and biomarkers associated with response
- Significantly contributed ideas and experiments to 13 scientific publications
- Provide guidance, training, and hands-on assistance to peers.
Senior Scientific Research
Genentech, Inc
01.2004 - 01.2013
- Develop, optimize, and validate in vivo mouse tumor models for use in oncology lead identification program
- Investigated the interplay between cancer cells and host immune system in murine tumor models; e.g
- Using magnetic cell separation, RT-PCR, protein array, tissue microarray, FACS and in vivo approaches verified IL-17, BV8, Resistin and PDGFc as mediators of anti-angiogenesis and radiation resistance
- Used in vivo models of oncology including subcutaneous and orthotopic xenografts, syngeneic, and leukemia models, post-Adeno-Cre delivery metastatic genetic engineering tumor models and imaging approaches to achieve deep understanding of the pathogenesis of tumor angiogenesis and angiogenesis-related processes;
- Design, manage, analyze, review, summarize, interpret and report results of in vivo pharmacology studies (primary and secondary pharmacology, mechanism of action, mechanism of disease, PK/PD, etc)
- E.g
- Provided in vivo data for second generation Avastin (Fc version, wide variety antibodies), anti-PDGFc and anti-BV8 to LSR or IND filling
- Provide strategic, scientific and leadership across functional research areas and program
- E.g
- Design of studies for gene expression profiling in preclinical tumor models and in patients tissue samples to identify PD and potential predictive biomarkers of response to anti-VEGF therapy
- Exploited a variety of genetically engineered mice to delete or modify leukocytes and investigated their angiogenesis functions on tumors growth and metastasis, identified and verified pharmacological blockade of TH17 cell function sensitized resistant tumors to therapy with antibodies to VEGF
- Design, conduct and interpret preclinical efficacy studies using mouse tumor models to test activity of drug candidates
- Incepted two patent applications for anti-BV8 and anti-angiogenesis medical therapies
- Significantly contributed ideas and experiments data for 23 scientific publications
Research scientist
Rigel Pharmaceuticals Inc
01.2003 - 01.2004
- Developed and validated in vivo bronchoconstrictin and airway inflammation asthma animal models to evaluate the pharmacology efficacy of small molecules Syk kinase inhibitor drug candidates
- Designed, implemented, tracked, summarized in vitro cellular and in vivo pharmacology techniques to investigate inhalation drug candidate molecule absorption across the lung barrier and their relation to drug physicochemical properties
- Used cytokines induction measurements and histology influence to establish drug candidate evaluation methods; formulated small molecules agent for pre-clinical in vivo use
- Designed, implemented, tracked, and conducted PK/PD animal study and PK data analyses with WinNonlin Software
- Conducted in formulation of small molecules hit-to-lead optimization required.
Research scientist
Metabolex Pharmaceuticals Inc
01.2002 - 01.2003
- Evaluated drug candidates for in vivo animal models; including PK/ADME evaluation for bioavailability and bioequivalence, and PD evaluation for efficacy
- Screened drug candidate’s potency and efficacy for Type II diabetes and Type II diabetes-related cardiovascular diseases with animal models including ob/ob and db/db mice, ZDF and ZF rats, high fat, high sugar and STZ-induced rat
- Designed and performed drug candidate mechanistic studies including IPGTT, euglycemic clamp, muscle and fat glucose uptake, glycogen synthesis /breakdown, pancreatic insulin secretion and liver metabolism
- Designed and performed drug candidate acute and sub-acute toxicity studies, tissue bio-distribution and bio-metabolism studies and quality control testing for release and stability studies.
Postdoctoral fellow
UC Davis Cancer Center
01.2001 - 01.2002
- Identified tumor specific ligands and their cell surface receptors in brain, lung and liver tumor cell lines with different combinatorial chemistry libraries of small molecules and peptides
- Expressed and purified and characterized proteins in baculovirus system including PTK Src family members of Fyn, Lck and Hck for selection cancer target
- Elucidated and validated the functions of these genes using assays including cell proliferation, apoptosis and cell migration
- Designed and developed sickle cell anemia mouse model for testing drug targets function.
Research scientist
Genaco Biomedical Products, Inc
01.2000 - 01.2001
- Developed and performed molecular diagnosis kits for cancer, infectious diseases and Down's syndrome by using a technology platform of Luminex 100
- Developed and performed methods of PCR, RT-PCR, DNA extraction, DNA ligation and DNA sequence analysis, biochemical analysis of proteins, immunohistochemistry, Western Blotting and ELISA for validation of cancer targets.
Research scientist
Perkin-Elmer Life Sciences
01.1997 - 01.2000
- Using fluorescence resonance energy transfer and indirect immunofluorescence on whole cells technology optimized and validated High Throughput Screening assays for cancer marks and interpreted and reported results
- Collaborated with Turku University, optimized and validated series of products of DELFIA PSA Free/Total Kit, Wallac AutoDELFIA thyroid function kits and Hemoglobin Test Kits
- Performed in vitro drug metabolism, cytochrome P450 and drug-drug interaction studies, as well as identification of drug metabolites
- Developed HPLC methods for drug substance and developed sample preparation techniques (protein precipitation, solid phase extraction) for subsequent sample analysis
- Adhered to established methods and SOPs, quality control procedures and preventive maintenance schedules.
Research associate scientist
Pharmacology University of Tampere
01.1992 - 01.1996
- Used endothelial cell function/ nitric oxide, vascular reactivity, characterization of flow in isolated vessel, cell signaling and animal models to investigate basic mechanisms of cardiovascular disease and vascular structure and function
- Developed in vivo animal cardiovascular disease models included rat model of spontaneous hypertension, rabbit and rat models of arteriosclerosis, salt and deoxycorticosterone rat model, Type II diabetes model
- Used diet inducing mouse and rat embolic stroke model to evaluate cardiovascular and anticoagulation parameters included blood pressure, thromboxane, atrial natriuretic peptide, LDL, organ bath in vitro vessel reaction and median infarct size;
- Contributed ideas and experiments to co-workers used in around 30 scientific publications.
R&D Director
Fangda Medical Co. Ltd
01.1986 - 01.1991
- Supervised and managed daily operations in protocol and experiment design, data analysis, research reporting and regulatory documentation preparation and data presentation
- Leading formulation tasks or projects to meet the needs for new liquid, solid dosage form or controlled release development
- Designed, organized, performed and interpreted data from experiments investigating the drug metabolism and PK/PD properties of drugs and drug delivery platforms
- Small molecular formulation and quality control of drug substance for release and stability tests.
Pharmaceutical teaching assistant, lecturer
Liaoning TCM University
01.1981 - 01.1984
- Taught Pharmaceutical Course fundamentals and lab experimentation to pharmacy students 120 hours/year
- Liaised with research biologists to provide advice on the development and modification of in vitro and in vivo models to support the generation of data to support / populate and validate translatable PK/PD models
- Extensive experience in isolating and characterizing biologically active compounds from herb and animal constituents for new drug leads
- Protein purification and characterization, (chromatography such as, affinity, ion-exchange, hydrophobic, and size exclusion) from herbs
- Used models CCl4 or bile duct ligation of experimental hepatic fibrosis evaluated herb medicine
- Carried out Morris water-maze testing, biochemical assays of Ach, ChAT and AchE, immunohistochemical Staining and bielshovsky sliver staining in brain tissue evaluating herb elements activity (components like Phenolic ketones, Ginkgo flavonoids, Liquiritin, Soy isoflavones and Matrine etc) on Alzheimer's disease.
Education
PhD - Pharmacology
Tampere University
MS - Pharmacology
Zhejiang TCM University
BS - Pharmacy Liaoning
TCM University
Skills
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
Hart S Dengler 1, Xiumin Wu 2, Ivan Peng 2, Cornelia H Rinderknecht 2, Youngsu Kwon 2, Eric Suto 2, Pawan Bir Kohli 3, Marya Liimatta 3, Kathy Barrett 3, Julia Lloyd 4, Gary Cain 5, Mike Briggs 6, Stephanie Addo 6, Gary Salmon 4, Savita Ubhayakar 7, Gauri Deshmukh 7, Sheerin K Shahidi-Latham 7, Cristine M Quiason-Huynh 7, Janet Jackman 1, John Liu 2, Nicholas C Ray 8, Simon C Goodacre 8, Adam Johnson 3, Brent S McKenzie 2, Wyne P Lee 2, Mark Zak 9, Jane R Kenny 5, Nico Ghilardi 10
Affiliations expand
PMID: 30463918 DOI: 101126/scitranslmedaao2151
Obligate role for Rock1 and Rock2 in adult stem cell viability and function
Sambandam A, Storm E, Tauc H, Hackney JA, Garfield D, Caplazi P, Liu J, Zhang J, Zhang H, Duggan J, Jeet S, Gierke S, Chang P, Wu X, Newman R, Tam L, Alcantar T, Wang L, Roose-Girma M, Modrusan Z, Lee WP, Jasper H, de Sauvage F, Pappu R
Hart S Dengler1, Xiumin Wu2, Ivan Peng2, Cornelia H Rinderknecht2, Youngsu Kwon2, Eric Suto2, Pawan Bir Kohli3, Marya Liimatta3, Kathy Barrett3, Julia Lloyd4, Gary Cain5, Mike Briggs6, Stephanie Addo6, Gary Salmon4, Savita Ubhayakar7, Gauri Deshmukh7, Sheerin K Shahidi-Latham7, Cristine M Quiason-Huynh7, Janet Jackman1, John Liu2, Nicholas C Ray8, Simon C Goodacre8, Adam Johnson3, Brent S McKenzie2, Wyne P Lee2, Mark Zak9, Jane R Kenny5 and Nico Ghilardi1
Science Translational Medicine Nov 2018
Kähönen M, Tolvanen JP, Kalliovalkama J, Wu X, Karjala K, Mäkynen H, Pörsti I
Eur J Pharmacol 1999 Mar 5;368(2-3):213-22
Influence of chronic ethanol consumption on arterial tone in young and aged rats
Kähönen M, Karjala K, Hutri-Kähönen N, Wu X, Jaatinen P, Riihioja P, Hervonen A, Pörsti I
Am J Physiol 1999 Feb;276(2 Pt 2):H464-71
Comparison of the effects of supplementation with whey mineral and potassium on arterial tone in experimental hypertension
Wu X, Tolvanen JP, Hutri-Kähönen N, Kähönen M, Mäkynen H, Korpela R, Ruskoaho H, Karjala K, Pörsti I
Cardiovasc Res 1998 Nov;40(2):364-74
Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro
Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Sisto T, Lähteenmäki T, Ylitalo P, Pörsti I
Pharmacol Toxicol 1998 Sep;83(3):125-31
Variations of arterial responses in vitro in different sections of rat main superior mesenteric artery
Tolvanen JP, Sallinen K, Wu X, Kähönen M, Arvola P, Pörsti I
Pharmacol Toxicol 1998 Aug;83(2):75-82
Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats
Lönnrot K, Pörsti I, Alho H, Wu X, Hervonen A, Tolvanen JP
Br J Pharmacol 1998 Aug;124(7):1500-6 Erratum in: Br J Pharmacol 1998 Dec;125(8):1788
Influence of gender on control of arterial tone in experimental hypertension
Kähönen M, Tolvanen JP, Sallinen K, Wu X, Pörsti I
Am J Physiol 1998 Jul;275(1 Pt 2):H15-22
Effects of calcium and potassium supplements on arterial tone in vitro in spontaneously hypertensive rats
Tolvanen JP, Mäkynen H, Wu X, Hutri-Kähönen N, Ruskoaho H, Karjala K, Pörsti I
Br J Pharmacol 1998 May;124(1):119-28
Arterial responses to bradykinin after ramipril therapy in experimental hypertension
Hutri-Kähönen N, Pörsti I, Wu X, Tolvanen JP, Sallinen K, Kähönen M
Pharmacol Toxicol 1997 Oct;81(4):190-6
Arterial function in mineralocorticoid-NaCl hypertension: influence of angiotensin-converting enzyme inhibition
Mäkynen H, Kähönen M, Wu X, Hutri-Kähönen N, Tolvanen JP, Pörsti I
Pharmacol Toxicol 1997 Oct;81(4):180-9
Ramipril therapy improves arterial dilation in experimental hypertension
Hutri-Kähönen N, Kähönen M, Tolvanen JP, Wu X, Sallinen K, Pörsti I
Cardiovasc Res 1997 Jan;33(1):188-95
Mesenteric arterial function in vitro in three models of experimental hypertension
Wu X, Mäkynen H, Kähönen M, Arvola P, Pörsti I
J Hypertens 1996 Mar;14(3):365-72
Effect of celiprolol therapy on arterial dilatation in experimental hypertension
Tolvanen JP, Wu X, Kähönen M, Sallinen K, Mäkynen H, Pekki A, Pörsti I
Br J Pharmacol 1996 Nov;119(6):1137-44
Whey mineral supplementation and arterial tone in mineralocorticoid-NaCl hypertension
Wu X, Mäkynen H, Korpela R, Pörsti I
Cardiovasc Res 1996 Dec;32(6):1115-22
Angiotensin-converting enzyme inhibition attenuates arterial constrictor responses in experimental hypertension
Kähönen M, Mäkynen H, Wu X, Arvola P, Pekki A, Pörsti I
J Pharmacol Exp Ther 1996 Jun;277(3):1701-9
Reversal of hypertension and endothelial dysfunction in deoxycorticosterone-NaCl-treated rats by high-Ca2 diet
Mäkynen H, Kähönen M, Wu X, Wuorela H, Pörsti I
Am J Physiol 1996 Apr;270(4 Pt 2):H1250-7
Endothelial function in deoxycorticosterone-NaCl hypertension: effect of calcium supplementation
Mäkynen H, Kähönen M, Wu X, Arvola P, Pörsti I
Circulation 1996 Mar 1;93(5):1000-8
Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment
Kähönen M, Mäkynen H, Wu X, Arvola P, Pörsti I
Br J Pharmacol 1995 Jul;115(5):859-67
Arterial contractions induced by cumulative addition of calcium in hypertensive and normotensive rats: influence of endothelium
Kähönen M, Arvola P, Wu X, Pörsti I
Naunyn Schmiedebergs Arch Pharmacol 1994 Jun;349(6):627-36
Effects of P1 and P2Y purinoceptor antagonists on endothelium-dependent and -independent relaxations of rat mesenteric artery to GTP and guanosine
Vuorinen P, Wu X, Arvola P, Vapaatalo H, Pörsti I
Certification
co-first author or first author
Additional Information
- HONORS , Youth researcher advanced prize from Tampere University, Finland. 1996.
- Br J Pharmacol. 1994 May;112(1):71-4. 7 publications in Chinese upon request.
Timeline
Life science Sr, Scientist
Calico
02.2024 - Current
therapeutics Sr Pharmacology manager
Nkarta
01.2019 - 02.2021
Senior Scientific Research
Genentech, Inc
01.2013 - 06.2019
Senior Scientific Research
Genentech, Inc
01.2004 - 01.2013
Research scientist
Rigel Pharmaceuticals Inc
01.2003 - 01.2004
Research scientist
Metabolex Pharmaceuticals Inc
01.2002 - 01.2003
Postdoctoral fellow
UC Davis Cancer Center
01.2001 - 01.2002
Research scientist
Genaco Biomedical Products, Inc
01.2000 - 01.2001
Research scientist
Perkin-Elmer Life Sciences
01.1997 - 01.2000
Research associate scientist
Pharmacology University of Tampere
01.1992 - 01.1996
R&D Director
Fangda Medical Co. Ltd
01.1986 - 01.1991
Pharmaceutical teaching assistant, lecturer
Liaoning TCM University
01.1981 - 01.1984
PhD - Pharmacology
Tampere University
MS - Pharmacology
Zhejiang TCM University
BS - Pharmacy Liaoning
TCM University